Topotecan weekly bolus chemotherapy for relapsed platinum-sensitive ovarian and peritoneal cancers

OBJECTIVE: Topotecan at a dose of 1.5 mg/m(2) on days 1 to 5 of a 21-day cycle is an approved therapy for recurrent ovarian cancer. However, heavily pretreated patients may be predisposed to hematologic adverse events. This prospective study, therefore, investigates the safety and efficacy of an alt...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: Morris, Robert, Alvarez, Ronald D., Andrews, Stephen, Malone, John, Bryant, Christopher, Heilbrun, Lance K., Smith, Daryn, Schimp, Veronica, Munkarah, Adnan
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: 2008
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC3865862/
https://ncbi.nlm.nih.gov/pubmed/18410954
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2008.02.028
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg